Need Help?

Expression-Based Subtypes Define Pathologic Response to Neoadjuvant Immune-Checkpoint Inhibitors in Muscle-Invasive Bladder Cancer

Checkpoint immunotherapy (CPI) has increased survival for some patients with advanced stage bladder cancer (BCa). However, most patients do not respond. Here, we characterized the tumor and immune microenvironment in pre- and post-treatment tumors from the PURE01 neoadjuvant pembrolizumab immunotherapy trial, using a consolidative approach that combined transcriptional and genetic profiling with digital spatial profiling.

Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data

Dataset ID Description Technology Samples
EGAD00001007998 Illumina HiSeq 4000 4
EGAD00001007999 Illumina NovaSeq 6000 6
EGAD00001008000 Illumina NovaSeq 6000 6
EGAD00001008001 Illumina HiSeq 2500 12
EGAD00001008002 Illumina HiSeq 2500 31
EGAD00001008003 Illumina HiSeq 4000 82
Publications Citations
Expression-based subtypes define pathologic response to neoadjuvant immune-checkpoint inhibitors in muscle-invasive bladder cancer.
Nat Commun 14: 2023 2126